Oppenheimer Holdings Inc. began coverage on shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) in a report released on Tuesday. The brokerage issued a market perform rating on the biopharmaceutical company’s stock.

AGIO has been the topic of several other research reports. Leerink Swann reiterated a market perform rating on shares of Agios Pharmaceuticals in a report on Friday, November 4th. BTIG Research initiated coverage on Agios Pharmaceuticals in a research note on Friday, August 19th. They issued a neutral rating on the stock. Zacks Investment Research upgraded Agios Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, October 19th. Goldman Sachs Group Inc. restated a neutral rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research note on Wednesday, August 10th. Finally, Credit Suisse Group AG restated a buy rating on shares of Agios Pharmaceuticals in a research note on Monday, November 21st. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $61.94.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at 61.37 on Tuesday. Agios Pharmaceuticals has a 52-week low of $33.50 and a 52-week high of $67.98. The company’s market capitalization is $2.58 billion. The stock has a 50 day moving average price of $54.70 and a 200 day moving average price of $48.50.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.52) by $0.11. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. The business had revenue of $8.98 million for the quarter, compared to the consensus estimate of $7.82 million. During the same quarter last year, the firm earned ($1.07) EPS. The company’s revenue for the quarter was up 63.9% on a year-over-year basis. On average, analysts predict that Agios Pharmaceuticals will post ($5.15) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Agios Pharmaceuticals Inc. (AGIO) Coverage Initiated by Analysts at Oppenheimer Holdings Inc.” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2016/11/30/agios-pharmaceuticals-inc-agio-coverage-initiated-by-analysts-at-oppenheimer-holdings-inc.html.

In other news, Director Lewis Clayton Jr. Cantley sold 627 shares of the stock in a transaction on Tuesday, September 27th. The stock was sold at an average price of $54.15, for a total transaction of $33,952.05. Following the sale, the director now directly owns 109,659 shares of the company’s stock, valued at approximately $5,938,034.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Scott Biller sold 5,000 shares of the stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $55.00, for a total value of $275,000.00. Following the sale, the insider now directly owns 48,270 shares in the company, valued at $2,654,850. The disclosure for this sale can be found here. 10.55% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the company. AlpInvest Partners B.V. bought a new stake in Agios Pharmaceuticals during the second quarter valued at about $1,257,000. Emerald Acquisition Ltd. acquired a new stake in shares of Agios Pharmaceuticals during the second quarter valued at $319,000. BlackRock Advisors LLC increased its stake in shares of Agios Pharmaceuticals by 1,942.6% in the second quarter. BlackRock Advisors LLC now owns 253,023 shares of the biopharmaceutical company’s stock valued at $10,600,000 after buying an additional 240,636 shares in the last quarter. Capital Fund Management S.A. acquired a new stake in shares of Agios Pharmaceuticals during the second quarter valued at $1,250,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Agios Pharmaceuticals by 425.5% in the second quarter. JPMorgan Chase & Co. now owns 30,882 shares of the biopharmaceutical company’s stock valued at $1,294,000 after buying an additional 25,005 shares in the last quarter. 89.27% of the stock is currently owned by institutional investors.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.